Home > Publications database > Anti-cancer therapy is associated with long-term epigenomic changes in childhood cancer survivors. > print

001     179389
005     20240229145542.0
024 7 _ |a 10.1038/s41416-022-01792-9
|2 doi
024 7 _ |a pmid:35354948
|2 pmid
024 7 _ |a 0007-0920
|2 ISSN
024 7 _ |a 1532-1827
|2 ISSN
024 7 _ |a altmetric:125602614
|2 altmetric
037 _ _ |a DKFZ-2022-00640
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Robinson, Natassia
|b 0
245 _ _ |a Anti-cancer therapy is associated with long-term epigenomic changes in childhood cancer survivors.
260 _ _ |a Edinburgh
|c 2022
|b Nature Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1662032094_21383
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2022 Jul;127(2):288-300
520 _ _ |a Childhood cancer survivors (CCS) exhibit significantly increased chronic diseases and premature death. Abnormalities in DNA methylation are associated with development of chronic diseases and reduced life expectancy. We investigated the hypothesis that anti-cancer treatments are associated with long-term DNA methylation changes that could be key drivers of adverse late health effects.Genome-wide DNA methylation was assessed using MethylationEPIC arrays in paired samples (before/after therapy) from 32 childhood cancer patients. Separately, methylation was determined in 32 samples from different adult CCS (mean 22-years post-diagnosis) and compared with cancer-free controls (n = 284).Widespread DNA methylation changes were identified post-treatment in childhood cancer patients, including 146 differentially methylated regions (DMRs), which were consistently altered in the 32 post-treatment samples. Analysis of adult CCS identified matching methylation changes at 107/146 of the DMRs, suggesting potential long-term retention of post-therapy changes. Adult survivors also exhibited epigenetic age acceleration, independent of DMR methylation. Furthermore, altered methylation at the DUSP6 DMR was significantly associated with early mortality, suggesting altered methylation may be prognostic for some late adverse health effects in CCS.These novel methylation changes could serve as biomarkers for assessing normal cell toxicity in ongoing treatments and predicting long-term health outcomes in CCS.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Casement, John
|b 1
700 1 _ |a Gunter, Marc J
|b 2
700 1 _ |a Huybrechts, Inge
|0 0000-0003-3838-855X
|b 3
700 1 _ |a Agudo, Antonio
|b 4
700 1 _ |a Barranco, Miguel Rodríguez
|0 0000-0002-9972-9779
|b 5
700 1 _ |a Eichelmann, Fabian
|b 6
700 1 _ |a Johnson, Theron
|0 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa
|b 7
|u dkfz
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 8
|u dkfz
700 1 _ |a Pala, Valeria
|0 0000-0001-5438-970X
|b 9
700 1 _ |a Panico, Salvatore
|b 10
700 1 _ |a Sandanger, Torkjel M
|b 11
700 1 _ |a Schultze, Matthias B
|b 12
700 1 _ |a Travis, Ruth C
|b 13
700 1 _ |a Tumino, Rosario
|0 0000-0003-2666-414X
|b 14
700 1 _ |a Vineis, Paolo
|b 15
700 1 _ |a Weiderpass, Elisabete
|0 0000-0003-2237-0128
|b 16
700 1 _ |a Skinner, Roderick
|b 17
700 1 _ |a Sharp, Linda
|0 0000-0001-9515-1722
|b 18
700 1 _ |a McKay, Jill A
|b 19
700 1 _ |a Strathdee, Gordon
|0 0000-0001-9681-8429
|b 20
773 _ _ |a 10.1038/s41416-022-01792-9
|0 PERI:(DE-600)2002452-6
|n 2
|p 288-300
|t British journal of cancer
|v 127
|y 2022
|x 0007-0920
909 C O |p VDB
|o oai:inrepo02.dkfz.de:179389
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRIT J CANCER : 2021
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-15
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-15
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BRIT J CANCER : 2021
|d 2022-11-15
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21